MRI Atlas of Prostate Cancer analyses high-resolution MRI scanning and dynamic contrast-enhanced (DCE) MRI. This combination improves the diagnosis and staging of prostate cancer and may soon replace PSA testing and digital rectal examination. The first two chapters focus on normal anatomy, anatomic variations, benign disease and intraprostatic tumors. The subsequent chapters on MRI of extracapsular disease create a useful atlas of pathologic anatomy. This is the first text of its kind to show color-coded DCE-MRI scans of prostate cancer and to correlate these imaging findings with tumor grading. The chapters on the post-treatment prostate clearly display the increasing incidence of post-therapy recurrences. This book is intended for internists, radiologists, radiotherapists, oncologists, urologists, family practitioners, and general surgeons. Ultrasound, MRI, and radiotherapy technicians will find it extremely useful as a reference guide.

This atlas provides a comprehensive, state of the art review of the use of multiparametric MRI (mpMRI) for the imaging of prostate cancer, covering aspects from diagnosis and loco-regional staging through to the role of the technique after treatment and follow-up. The book contains a wealth of high-resolution images, many of them in color, and displays the anatomical-MRI–pathological correlation whenever appropriate. Readers will find a helpful overview on the current standardized method for reading and reporting on mpMRI, the Prostate Imaging Reporting and Data System (PI-RADS), version 2. Dedicated chapters focus on differential diagnosis and imaging pitfalls, and the inclusion of helpful diagrams and algorithms will further assist in image interpretation, enabling readers to ease and improve their use of mpMRI. Edited and written by very experienced radiologists, pathologists, and urologists; the Atlas of Multiparametric Prostate MRI will serve as a unique source of clinically relevant information and an aid to disease management for radiologists, urologists, pathologists, radiotherapists, and oncologists.

This book covers novel strategies and state of the art approaches for automated non-invasive systems for early prostate cancer diagnosis. Prostate cancer is the most frequently diagnosed malignancy after skin cancer and the second leading cause of cancer related male deaths in the USA after lung cancer. However, early detection of prostate cancer increases chances of patients’ survival. Generally, The CAD systems analyze the prostate images in three steps: (i) prostate segmentation; (ii) Prostate description or feature extraction; and (iii) classification of the prostate status. Explores all of the latest research and developments in state-of-the art imaging of the prostate from world class experts. Contains a comprehensive overview of 2D/3D Shape Modeling for MRI data. Presents a detailed examination of automated segmentation of the prostate in 3D imaging. Examines Computer-Aided-Diagnosis through automated techniques. There will be extensive references at the end of each chapter to enhance further study.

Prostatic adenocarcinoma (CAP) is the second most common malignancy with an estimated 190,000 new cases in the USA in 2010 (Source: American Cancer Society), and is the most frequently diagnosed cancer among men. If CAP is caught early, men have a high, five-year survival rate. Unfortunately there is no standardized ima- based screening protocol for early detection of CAP (unlike for breast cancers). In the USA high levels of prostate-specific antigen (PSA) warrant a trans-rectal ultrasound (TRUS) biopsy to enable histologic confirmation of presence or absence of CAP. With recent rapid developments in multi-parametric radiological imaging te- niques (spectroscopy, dynamic contrast enhanced MR imaging, PET, RF ultrasound), some of these functional and metabolic imaging modalities are allowing for definition of high resolution, multi-modal signatures for prostate cancer in vivo. Distinct com- tational and technological challenges for multi-modal data registration and classifi- tion still remain in leveraging this multi-parametric data for directing therapy and optimizing biopsy. Additionally, with the recent advent of whole slide digital sc- ners, digitized histopathology has become amenable to computerized image analysis. While it is known that outcome of prostate cancer (prognosis) is highly correlated with Gleason grade, pathologists often have difficulty in distinguishing between interme- ate Gleason grades from histopathology. Development of computerized image analysis methods for automated Gleason grading and predicting outcome on histopathology have to confront the significant computational challenges associated with working these very large digitized images.

Objective:The main aim is to evaluate the value of dynamic contrast-enhanced (DCE) imaging in multi-parametric prostate MRI (mpMRI) for the detection and staging of prostate cancer in comparison with T2W and DWI images alone in biparametric MRI (bpMRI), in treatment nau00efve patients.Methods:One hundred consecutive patients who underwent a prostate MRI at our institution from June-August 2017, as well as a systematic ultrasound-guided prostate biopsy or prostatectomy, were included. Strictly following the PIRADSv2, the MRI studies were independently interpreted by a body radiologist and a body-imaging fellow on two different occasions 8-10 weeks apart. Initially, with all mpMRI sequences and then without the DCE sequence (bpMRI). The readers were blinded to the clinical information. Ethics approval was obtained.Results/Discussion:One hundred treatment-nau00efve patients were included (median age 64, age range 48-81, mean PSA 10.3). There was excellent intra-observer agreement of the mpMRI versus bpMRI for both readers [Cohenu2019s Kappa (k) 0.88-0.86] and very good inter-observer agreement (k=0.74 for mpMRI and 0.76 for bpMRI). The sensitivity and specificity did not significantly change between the multi-parametric and bi-parametric MRI (Sensitivity 91.7% and 90%, Specificity of 85.5% and 85% for mpMRI and bpMRI, respectively).Conclusion:Prostate MRI without DCE (bpMRI) is of comparable diagnostic accuracy to mpMRI in treatment-nau00efve patients. Performing prostate MRI without DCE (bpMRI) will reduce acquisition time, decrease cost and potentially improve patient safety.